Soft-Substrate hPSC-Derived Cardiomyocyte Maturation at Scale
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating cardiomyocytes from human pluripotent stem cells (hPSCs) produce immature cells that are limited in translational potential and can contribute to ventricular tachyarrhythmias, and are not scalable to produce large quantities required for regenerative cell therapy.
Innovation Solution
A method involving seeding human cardiac progenitor cells on a soft, biocompatible substrate like PDMS and culturing them in a cardiac medium with movement, using activators and antagonists of specific signaling pathways, to develop mature cardiomyocytes, which can be scaled up to large volumes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current protocols are used to generate hPSC-CMs, then cardiomyocytes can be produced, but the cells remain immature with limited translational potential and may contribute to ventricular tachyarrhythmias
Solution Approach 1:
The patent changes physical parameters (substrate stiffness from hard to soft), chemical parameters (medium composition with maturation factors), and temporal parameters (prolonged culture duration) to transform immature hPSC-CMs into mature cardiomyocytes with improved translational potential and safety profile
Solution Approach 2:
The patent applies preliminary maturation treatments during the culture process, including substrate preparation with appropriate stiffness, pre-addition of maturation factors to the medium, and staged differentiation protocols that prepare cells for mature phenotype before transplantation
2Reliability
If maturation methods such as prolonged culture, electromechanical conditioning, and hormone treatment are applied, then cardiomyocyte maturity improves, but scalability to produce large quantities (10^9 to 10^10 cells) is limited
Solution Approach 1:
The patent modifies culture parameters including substrate stiffness, medium composition, and oxygen tension to enable maturation processes that are compatible with large-scale production, moving away from low-throughput methods toward scalable protocols
Solution Approach 2:
The patent extracts and isolates the critical maturation-inducing factors (substrate stiffness, specific growth factors, oxygen levels) from complex in vivo environments, creating simplified in vitro conditions that maintain cell maturity while enabling scalable production
Data Source
AI summary
Provided herein are methods for large-scale in vitro maturation of cardiomyocytes derived from human pluripotent stem cells, compositions prepared by these methods, and use of these compositions in cardiac regeneration.